We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ultragenyx Pharmaceutical Announces FDA Acceptance of UX016 IND
Read MoreHide Full Article
Key Takeaways
RARE announces FDA acceptance of IND for UX016 to treat GNEM, a rare muscle disorder with no US therapies.
RARE plans a phase I/II study in H2 2026, enrolling 24 adults, to assess safety and efficacy vs. placebo.
UX016 uses a fatty acid tail to improve muscle delivery, aiming to overcome past therapy limitations.
Ultragenyx Pharmaceutical (RARE - Free Report) announced that the FDA has accepted its investigational new drug (IND) application for UX016, an investigational small-molecule prodrug of sialic acid, which is being developed as a substrate replacement therapy for GNE myopathy (GNEM).
GNEM, also known as hereditary inclusion body myopathy or Nonaka myopathy, is a rare inherited neuromuscular disorder caused by reduced production of sialic acid. This deficiency leads to progressive muscle wasting, resulting in severe disability and loss of mobility. Currently, there are no approved treatments for this disease in the United States.
Year to date, RARE’s shares have lost 16.1% against the industry’s 0.3% growth.
Image Source: Zacks Investment Research
Clinical Development Plan
The program is being externally funded by a patient organization through early clinical development, with the first-in-human phase I/II study expected to be initiated in the second half of 2026 in the United States.
Study Design & Endpoints
The study will enroll approximately 24 adults aged 18 to 55 years with GNEM. It will assess the safety, effectiveness and pharmacokinetics of UX016, including its delivery to the muscle. Participants will be given two dose levels compared with placebo over the initial 12 weeks, followed by continued evaluation of muscle strength, patient-reported outcomes and overall functional improvements through 48 weeks of treatment.
UX016 is a prodrug that combines sialic acid with a hydrophobic fatty acid tail to improve its delivery to muscle compared with natural sialic acid. It is designed to overcome limitations that have reduced the effectiveness of earlier substrate replacement therapies.
RARE’s Commercial Portfolio
Ultragenyx Pharmaceutical has built a portfolio of four therapies, namely Crysvita, Mepsevii, Dojolvi and Evkeeza. Crysvita is approved for treating X-linked hypophosphatemia, an inherited disorder and tumor-induced osteomalacia, an ultra-rare disease. Mepsevii is approved to treat mucopolysaccharidosis VII, also known as Sly syndrome. Dojolvi is approved for the treatment of all forms of long-chain fatty acid oxidation disorders. Evkeeza is indicated for homozygous familial hypercholesterolemia.
RARE's Zacks Rank & Stocks to Consider
Ultragenyx Pharmaceutical currently carries a Zacks Rank #3 (Hold).
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 earnings per share have risen from $2.55 to $2.87. CPRX shares have lost 0.6% over the past year.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have risen from $2.89 to $3.08. INDV shares have surged 206.8% over the past year.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 74.53%.
Over the past 60 days, estimates for ANI Pharmaceuticals’ earnings per share have increased from $8.28 to $8.99 for 2026. Over the past year, shares of ANIP have rallied 8.4%.
ANI Pharmaceuticals' earnings beat estimates in each of the trailing four quarters, with the average surprise being 22.21%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Ultragenyx Pharmaceutical Announces FDA Acceptance of UX016 IND
Key Takeaways
Ultragenyx Pharmaceutical (RARE - Free Report) announced that the FDA has accepted its investigational new drug (IND) application for UX016, an investigational small-molecule prodrug of sialic acid, which is being developed as a substrate replacement therapy for GNE myopathy (GNEM).
GNEM, also known as hereditary inclusion body myopathy or Nonaka myopathy, is a rare inherited neuromuscular disorder caused by reduced production of sialic acid. This deficiency leads to progressive muscle wasting, resulting in severe disability and loss of mobility. Currently, there are no approved treatments for this disease in the United States.
Year to date, RARE’s shares have lost 16.1% against the industry’s 0.3% growth.
Image Source: Zacks Investment Research
Clinical Development Plan
The program is being externally funded by a patient organization through early clinical development, with the first-in-human phase I/II study expected to be initiated in the second half of 2026 in the United States.
Study Design & Endpoints
The study will enroll approximately 24 adults aged 18 to 55 years with GNEM. It will assess the safety, effectiveness and pharmacokinetics of UX016, including its delivery to the muscle. Participants will be given two dose levels compared with placebo over the initial 12 weeks, followed by continued evaluation of muscle strength, patient-reported outcomes and overall functional improvements through 48 weeks of treatment.
UX016 is a prodrug that combines sialic acid with a hydrophobic fatty acid tail to improve its delivery to muscle compared with natural sialic acid. It is designed to overcome limitations that have reduced the effectiveness of earlier substrate replacement therapies.
RARE’s Commercial Portfolio
Ultragenyx Pharmaceutical has built a portfolio of four therapies, namely Crysvita, Mepsevii, Dojolvi and Evkeeza. Crysvita is approved for treating X-linked hypophosphatemia, an inherited disorder and tumor-induced osteomalacia, an ultra-rare disease. Mepsevii is approved to treat mucopolysaccharidosis VII, also known as Sly syndrome. Dojolvi is approved for the treatment of all forms of long-chain fatty acid oxidation disorders. Evkeeza is indicated for homozygous familial hypercholesterolemia.
RARE's Zacks Rank & Stocks to Consider
Ultragenyx Pharmaceutical currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Catalyst Pharmaceuticals (CPRX - Free Report) and Indivior Pharmaceuticals (INDV - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy), and ANI Pharmaceuticals (ANIP - Free Report) , which presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 earnings per share have risen from $2.55 to $2.87. CPRX shares have lost 0.6% over the past year.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have risen from $2.89 to $3.08. INDV shares have surged 206.8% over the past year.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 74.53%.
Over the past 60 days, estimates for ANI Pharmaceuticals’ earnings per share have increased from $8.28 to $8.99 for 2026. Over the past year, shares of ANIP have rallied 8.4%.
ANI Pharmaceuticals' earnings beat estimates in each of the trailing four quarters, with the average surprise being 22.21%.